| Literature DB >> 12113828 |
Nicolas Inguimbert1, Hervé Poras, Franck Teffo, Françoise Beslot, Mohamed Selkti, Alain Tomas, Elizabeth Scalbert, Caroline Bennejean, Pierre Renard, Marie-Claude Fournié-Zaluski, Bernard-Pierre Roques.
Abstract
We have previously reported the design of a lead compound 1a for the joint inhibition of neprilysin (NEP, EC 3.4.24.11), angiotensin converting enzyme (ACE, EC 3.4.15.1) and endothelin converting enzyme (ECE-1, EC 3.4.24.71), three metallopeptidases which are implicated in the regulation of fluid homeostasis and vascular tone. We report here the synthesis and biological activities of analogues derived from this lead with inhibitory potencies in the nanomolar range for the three enzymes. Compounds 8b and 15c are the most potent triple inhibitors described to date.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12113828 DOI: 10.1016/s0960-894x(02)00248-2
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823